主要投资者调整了诺华公司的股权,据报告,诺华公司的收入比预期的要高。 Major investors adjusted stakes in Novartis, which reported stronger-than-expected earnings.

几个主要投资者在第四季度调整了诺华股份有限公司的股份,哈特福德基金管理有限公司增加了9.6%,马尔科投资管理有限公司减少了2.0%的股份。 Several major investors adjusted their stakes in Novartis AG in the fourth quarter, with Hartford Funds Management Co LLC increasing its position by 9.6% and Marco Investment Management LLC reducing holdings by 2.0%. Novartis报告说,最后一个季度的EPS比预期的要强198美元,增加0.18美元,分析家预测该年度的EPS为8.45美元。 Novartis reported a stronger-than-expected $1.98 EPS for the last quarter, beating estimates by $0.18, and analysts forecast 8.45 EPS for the year. 瑞士制药公司专门从事心血管病、肾病和代谢病、免疫学、神经科学和肿瘤学等治疗领域。 The Swiss pharmaceutical company specializes in therapeutic areas including cardiovascular, renal and metabolic conditions, immunology, neuroscience, and oncology.